MarketCap
Facebook
X
TelegramQuartalsbericht 2025-Q3
hinzugefügt 06.11.2025
Caladrius Biosciences Operativer Cashflow 2011-2026 | CLBS
Operativer Cashflow Jährlich Caladrius Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -19.4 M | -20 M | -21.2 M | -22.2 M | -8.82 M | -18.9 M | -20 M | -20.9 M | -23.7 M | -39.3 M | -46.9 M | -27.1 M | -13.9 M | -20.9 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -8.82 M | -46.9 M | -23.1 M |
Operativer Cashflow Vierteljährlich Caladrius Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -5.4 M | - | - | - | -7.03 M | - | - | - | -8.2 M | - | -14.7 M | - | -5.64 M | - | -17.6 M | - | -7.98 M | - | -3.26 M | 262 K | -4.24 M | - | -14.7 M | -10.2 M | -5.49 M | - | -16.9 M | -12.2 M | -6.3 M | - | -16.9 M | -10.6 M | -10.1 M | - | -20.3 M | -14.6 M | -8.03 M | - | -30.5 M | -21.8 M | -14.2 M | - | -36 M | -22.5 M | -11.3 M | - | -19.7 M | -13.1 M | -7.14 M | - | -4.23 M | -852 K | 2.11 M | - | -17.5 M | -13.3 M | -10.2 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 2.11 M | -36 M | -11.9 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aptorum Group Limited
APM
|
-1.84 M | $ 0.89 | - | $ 6.54 M | China |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
158 M | $ 22.2 | - | $ 3.68 B |  USA |
 |
Edesa Biotech
EDSA
|
-4.89 M | $ 15.9 | - | $ 50.8 M | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Evogene Ltd.
EVGN
|
-24.7 M | $ 0.76 | - | $ 27.9 M |  Israel |
 |
Exelixis
EXEL
|
884 M | $ 44.69 | - | $ 12.1 B | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Galapagos NV
GLPG
|
-504 M | $ 27.86 | - | $ 2.69 B |  Belgium |
 |
Grifols, S.A.
GRFS
|
597 M | $ 7.91 | - | $ 6.83 B |  Spain |
 |
Harmony Biosciences Holdings
HRMY
|
348 M | $ 31.05 | - | $ 1.79 B | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | USA |
 |
ImmuCell Corporation
ICCC
|
2.48 M | $ 8.44 | - | $ 76.2 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-6.98 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioNTech SE
BNTX
|
890 M | $ 101.57 | - | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Immuron Limited
IMRN
|
-3.15 M | $ 0.81 | 0.3 % | $ 9.47 M |  Australia |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Incyte Corporation
INCY
|
1.41 B | $ 99.1 | - | $ 19.3 B | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
InMed Pharmaceuticals
INM
|
-7.28 M | $ 0.7 | - | $ 1.71 M | Canada |
 |
INmune Bio
INMB
|
-22.6 M | $ 1.33 | - | $ 32.9 M | USA |
 |
Innoviva
INVA
|
197 M | $ 23.05 | - | $ 1.55 B | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Innate Pharma S.A.
IPHA
|
-58.5 M | $ 1.48 | -0.67 % | $ 235 M | France |
 |
Jaguar Health
JAGX
|
-23.7 M | $ 7.88 | - | $ 18.4 M | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-81.6 M | $ 26.67 | - | $ 1.44 B | Britain |
 |
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Kamada Ltd.
KMDA
|
-8.82 M | $ 8.11 | - | $ 260 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 2.98 | - | $ 4.91 M | Israel |
 |
Krystal Biotech
KRYS
|
201 M | $ 259.95 | - | $ 7.52 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-22.8 M | $ 12.42 | - | $ 1.65 B | Australia |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
97 M | $ 224.86 | - | $ 4.11 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Liquidia Corporation
LQDA
|
-35.7 M | $ 38.15 | - | $ 3.28 B | USA |
 |
Applied Therapeutics
APLT
|
-55.2 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aquestive Therapeutics
AQST
|
-52.4 M | $ 4.05 | - | $ 433 M | USA |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |